REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Maurice Perol
Consultant or Advisory Role - Boehringer Ingelheim (U); Genentech (U); Lilly (U); Pfizer (U); Roche (U)
Honoraria - Genentech; Lilly; Pfizer; Roche
Other Remuneration - Genentech; Lilly; Roche
Tudor-Eliade Ciuleanu
Honoraria - Lilly
Oscar Arrieta
No relevant relationships to disclose
Kumar Prabhash
No relevant relationships to disclose
Konstantinos N. Syrigos
No relevant relationships to disclose
Tuncay Göksel
Research Funding - Lilly
Keunchil Park
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis; Lilly; Roche
Research Funding - AstraZeneca
Ruben Dario Kowalyszyn
No relevant relationships to disclose
Joanna Pikiel
No relevant relationships to disclose
Grzegorz Czyzewicz
No relevant relationships to disclose
Sergey Orlov
No relevant relationships to disclose
Conrad R. Lewanski
Honoraria - Lilly
Research Funding - Lilly
Ekaterine Alexandris
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Annamaria Zimmerman
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Nadia Chouaki
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
William J. John
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sergey Yurasov
Employment or Leadership Position - ImClone Systems
Edward B. Garon
Consultant or Advisory Role - Lilly (U)
Research Funding - Lilly